No Data
Impressive performance has not been able to boost the stock price, what is the true value of innocare (09969) core products?
On the other hand of high growth, the success of obinutuzumab has not yet managed to turn around innocare's losses.
Express News | InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of Tyk2 Inhibitor Icp-332 for the Treatment of Atopic Dermatitis in China
The InnoCare Pharma Limited (HKG:9969) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Selected Announcement | leapmotor Q3 revenue increased by 74.3% year-on-year to 9.86 billion yuan; q tech October camera module sales increased by over 10%
① china life insurance's original premium income exceeded 620 billion yuan this year, what is the growth rate? ② q tech's camera module sales in October increased by over 10%, what highlights are there in other business?
Nuochengjianhua Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Gelonghui Announcement Highlights (Hong Kong Stocks) | Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan, expected to exceed the annual gross margin target.
【Today's Focus】Leapmotor (09863.HK) third-quarter revenue increased by 74.3% year-on-year to 9.86 billion yuan. Expected to exceed the annual gross margin target Leapmotor (09863.HK) announced that in the third quarter of 2024, the company's revenue was 9.86 billion yuan, an 83.9% increase from the second quarter, a 74.3% increase from 2023, mainly due to the significant increase in product delivery volume and optimization of product sales structure. The gross margin in the third quarter of 2024 was 8.1%, a significant improvement from 2.8% in the second quarter of 2024.
No Data
No Data
